Booth M33 – Hall Maillot, Level 2.
“Interim data from an ongoing study show: pressure-controlled intermittent coronary sinus occlusion results in cardioprotection when given adjunct to PCI”
Jain, Barts Heart Centre, London, UK
Abstract Euro17A-OP1053, presented during: Novel approaches for treatment of STEMI – Session comprising selected EuroPCR 2017 abstract submissions
TUESDAY, MAY 16, 2017, 3.30 PM, Room 252 A (Level 2)
Symposium sponsored by Miracor
TUESDAY, MAY 16, 2017, 5.15 PM – 6.45 PM, Room 241 (Level 2)
“Targeting infarct size reduction to prevent heart failure”
Chairpersons: G.W. Stone, Columbia University, New York, USA
A. Zaman, Freeman Hospital, Newcastle, UK
The coronary sinus reducer: clinical evidence and technical aspects
Pages 47-58 | Received 26 Sep 2016, Accepted 07 Dec 2016, Accepted author version posted online: 09 Dec 2016, Published online: 15 Dec 2016
Introduction: Chronic refractory angina is often a disabling condition, predominantly due to severe obstructive coronary artery disease, that is inadequately controlled by optimal medical therapy and not amenable to further percutaneous or surgical revascularization. mortality rates associated with this condition are relatively low in clinically stable patients. however, it is associated with a high hospitalization rate and a reduction in both exercise capacity and quality of life. due to the paucity of available treatment options, there is an unmet need for new therapies for these patients and for a reduction in the associated economic healthcare burden.
Areas covered: This review is focusing on the clinical evidence and technical aspects of this new therapeutic modality in refractory angina patients unsuitable for revascularization.
Expert commentary: The Coronary Sinus Reducer (Neovasc Inc. Richmond B.C., Canada) is a new percutaneous device designed to achieve a controlled narrowing of the coronary sinus that may alleviate myocardial ischemia, possibly by redistributing blood from the less ischemic sub-epicardium to the more ischemic sub-endocardium, or by neoangiogenesis. Recently, a randomized, double-blind, multi-center clinical trial demonstrated a benefit in improving symptoms in 104 refractory angina patients, when compared to placebo.
Neovasc Inc. today announced it has received both regulatory and ethics committee approval to initiate the Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA II) in Italy. TIARA II is a 115 patient, non-randomized, prospective clinical study evaluating the safety and performance of the Tiara™ Transcatheter Mitral Valve with the Tiara™ Transapical Delivery System (Tiara™).
With these critical approvals now in place, it is expected that the first Italian TIARA II clinical study site will be initiated before year end, with first enrollment anticipated early in the new year. Approvals in additional geographies are expected in the first quarter of 2017.
Due nuovi “Case Study” sono disponibili a supporto della promozione commerciale dell’innovativo sistema Acist RXi. Si tratta in particolare di un caso effettuato a Magonza dal Prof. Münzel e dal Dott. Schulz e di un altro effettuato a Mirano dal Dott. Turri.